OSLI Retina

September 2018

Issue link: http://osliretina.healio.com/i/1024748

Contents of this Issue

Navigation

Page 89 of 91

736 Ophthalmic Surgery, Lasers & Imaging Retina | Healio.com/OSLIRetina 6900 Grove Road Thorofare, NJ 08086-9447 Phone: 856-848-1000 Email: osli@healio.com Healio.com/OSLIRetina SLACK I N C O R P O R A T E D ® SLACK Incorporated Chief Content Officer Joan-Marie Stiglich, ELS EDITORIAL Senior Editorial Director David W. Mullin Executive Editor Cara Dickinson Operations Manager Cheryl McKeown Production Associate Ryan Davis SALES Group Sales Director, Eye Care Scott Wright National Account Manager Laura Renna Director, Sales Administration and Support Carolyn Boerner Sales Administrator Wanda Granato Recruitment/Classified Sales Representative Bernadette Hamilton Sales Coordinator, Recruitment Jennifer Carroll Director of Audience Development Stephanie McHugh Reprints/Eprints Licensing Opportunities: The Sheridan Press 800-635-7181 ext. 8065 DESIGN Creative Director Thomas Cavallaro The Wyanoke Group President Peter N. Slack Chief Operating Officer John C. Carter Chief Financial Officer Darrell Blood Senior Vice President Denise Mealey Chief Technology Officer Linda Baker Follow OSLIJournal OSLI Retina SLACK Incorporated News and Notes FDA Approves Eylea 12-Week Dosing for Wet AMD The U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for a 12-week dosing schedule of Eylea in- jection in wet age-related macular degeneration patients, Regeneron announced in a press release. The FDA previously issued a complete response letter to Regeneron regarding the sBLA, which is based on data from the phase 3 VIEW 1 and 2 trials, in which patients with wet AMD received Eylea (aflibercept; Regeneron, Tarrytown, NY) injections at least every 12 weeks, with additional doses as needed. "We are pleased that the FDA has approved an updated label for Eylea," George D. Yancopoulos, MD, PhD, president and chief scientific officer at Regen- eron, said in the release. "Providing information to retinal physicians about the visual outcomes with a modified 12-week dosing schedule will help physicians make the most informed choices in treating patients suffering from wet age-relat- ed macular degeneration." Eylea was already approved for dosing intervals of every 4 weeks or every 8 weeks, after three initial monthly doses, for wet AMD. Originally posted on Healio.com on August 17, 2018. Ophthalmic Surgery, Lasers & Imaging Retina® (ISSN-2325-8160, Canadian BN-12978 0466 RT ) is published 12 times per year by SLACK Incorporated®, and is an official publication of ARVO/ISIE. Publication Office: SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Telephone (856) 848-1000. Printed in the USA. Periodicals Class Postage Paid at Deptford, NJ 08096 and at additional mailing offices. Contents copyrighted by SLACK Incorporated®, 2018. All rights reserved. No part of this publication may be reproduced with- out prior written consent of the publisher. All requests to reprint or use material published herein should be directed to the Request Permissions link on every article page at Healio.com/ophthalmology/journals/osli. Subscription rates in the U.S. and possessions: Individuals: One year—print $213, electronic only: $190. Institutional: One year—$668. Residents and fellows: $107 for one year (a letter of certification indicating residency of the subscriber is required). Canada add 5% GST, all other countries add $58 per year. All subscriptions, without exception, will start with the first issue pub- lished after the order is received. Single copies and back issues, when available, are $96. Payment must accompany order. Subscrip- tion requests should be addressed to the publisher. Change of Address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new ad- dresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Duplicate copies will not be sent to re- place ones undelivered through failure to notify the publisher of change of address. POSTMASTER: Send Form 3547 to Ophthalmic Surgery, Lasers & Imaging Retina®, SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Articles are intended for informational purposes only and should not be used as the basis of patient treatment. All opinions expressed by authors and quoted sources are their own and do not necessarily reflect the opinions of the editors, publisher, or editorial boards of SLACK Incorporated®. The acceptance of advertising in no way implies endorsement by the editors, publisher, or editorial boards of SLACK Incorporated®. See website for print and web advertising policy. Readers with queries about the Journal's policies on error correction, version control, journal of record, ancillary material, or archiving should contact osli@healio.com. The Journal staff have no financial relationships to disclose. Financial disclosures for the Editor and members of the Editorial Board are on file with the editorial office. Indexed in: Medline/PubMed, ProQuest, EMCare, EMBASE, Science Citation Index, Current Contents/Clinical Medicine, BioEn- gineering Abstracts, CAB Abstracts, and SCOPUS.

Articles in this issue

Links on this page

Archives of this issue

view archives of OSLI Retina - September 2018